 This multi-center randomized Phase II study assigned HER2-negative early-stage breast cancer patients to receive preoperative systemic chemotherapy in either a genomic-guided arm or a non-guided arm. The genomic-guided method Arm 1 used genomic expression profiling to assign the preoperative therapy DoxorubicinCyclophosphamide AC versus DocetaxelCyclophosphamide TC, while Arm 2 used random assignment to these two therapies. 